KEKE克刻品牌怎么样 申请店铺

贵州益佰制药股份有限公司是一家集新型药品的研究、开发、生产和销售为一体的企业。公司创建于1995年6月12日，2000年11月完成股份制改造，并于2004年3月在上海证券交易所成功上市(证券代码600594)。

公司占地面积134398平方米，建有符合国家药品生产质量管理规范(简称GMP)的生产厂房43200平方米。目前拥有省内生产基地3个，省外生产基地4个。现有小针剂、冻干粉针、大输液等49个品规产品，9条注射剂生产线。

截止至2012年12月，公司工业产值近30亿元，销售收入近28亿元(集团合并数据)，2012年贵州省内纳税3.86亿元，公司成立至今累计向国家纳税已超过23亿元。2013年1-6月。

公司在发展过程中一直专注于完善公司治理，不断提高公司治理水平。

公司现有员工4000余人。公司本着“百年树人”的理念，始终给予员工培训工作极大的重视，对员工采取多种形式进行培训，通过学习培训，有效地提高了全体员工的工作积极性，使员工的整体素质得到了提升。公司高级管理人员送往清华大学、中欧国际工商学院、国研斯坦福、长江管理学院、上海交通大学等院校进行管理学习，并在公司内部举办总经理培训班，聘专家上课，挑选公司管理人员及部分员工参加，旨在提高管理人员的综合素质。

公司还将专业技术人员送往相关药学院进行专业培训，注重提高公司技术实力和培养创新精神;坚持工人培训制度，不断加强工人文化素质、修养、技术技能的提高，全公司员工严格按每年300个以上学时进行相应培训。

公司目前的主要产品有克咳家族系列、艾迪注射液、银杏达莫注射液、注射用洛铂、复方斑蝥胶囊、理气活血滴丸、前列癃闭通颗粒等众多优势品种。在这些已形成企业优势系列产品中，复方中药针剂艾迪注射液和复方斑蝥胶囊为双相抗肿瘤新药，其中艾迪注射液的研究已达到基因水平；第四代银杏制剂----银杏达莫注射液，是心、脑血管及外周循环障碍的有效治疗药物，它的面世为广大的心脑血管病患者带来了福音；注射用洛铂是国家一类新药，第三代铂类抗肿瘤药物，相对其他铂类，其毒性较低、耐药性较小。理气活血滴丸则是原研苗药，是治疗心血管疾病的一线用药，具有极大的市场潜力。

公司在全国主要城市建立了良好的营销网络，配备了训练有素的销售队伍，实现企业从产品到患者服务全过程的质量跟踪服务。

公司为促进医药产业结构优化，提高产品集中度，本着加速并购，自主创新的发展理念，在过去几年陆续收购了桂林漓江制药、云南南诏药业、贵州民族药业、海南长安制药等生产型制药企业，这些企业的品种已有很好的市场销售，并具有非常广阔的市场前景。2012年，益佰再次加速自己整合并购的步伐，收购北京爱德药业有限公司80%的股份，将基因工程药品的开发、生产、销售一举融入到益佰的医药健康产业链之中。

Guizhou Yibai Pharmaceutical Co., Ltd. is an enterprise integrating research, development, production and sales of new drugs. The company was founded on June 12, 1995, completed the share-holding transformation in November 2000, and successfully listed on the Shanghai Stock Exchange in March 2004 (Stock Code: 600594). The company covers an area of 134398 square meters, and has built 43200 square meters of production plants in line with the GMP. At present, it has 3 production bases in the province and 4 production bases outside the province. There are 49 products and 9 injection production lines including small injection, freeze-dried powder injection and large infusion. As of December 2012, the company's industrial output value is nearly 3 billion yuan, sales revenue is nearly 2.8 billion yuan (group consolidated data). In 2012, Guizhou province paid taxes of 386 million yuan, and the company has paid taxes to the state more than 2.3 billion yuan since its establishment. January June 2013. In the process of development, the company has been focusing on improving corporate governance and constantly improving the level of corporate governance. The company has more than 4000 employees. In line with the concept of "a hundred years of cultivation", the company has always attached great importance to the training of employees, and has taken various forms of training for employees. Through learning and training, the enthusiasm of all employees has been effectively improved, and the overall quality of employees has been improved. Senior managers of the company are sent to Tsinghua University, China Europe International Business School, national research Stanford, Yangtze River Management College, Shanghai Jiaotong University and other institutions for management study, and general manager training courses are held within the company, experts are invited to attend classes, and management personnel and some employees of the company are selected to participate, in order to improve the comprehensive quality of management personnel. The company also sent professional and technical personnel to relevant pharmaceutical colleges for professional training, focusing on improving the company's technical strength and cultivating the spirit of innovation; adhere to the workers' training system, and constantly strengthen the improvement of workers' cultural quality, cultivation and technical skills, and the company's employees receive corresponding training in strict accordance with more than 300 class hours per year. At present, the company's main products include Keke family series, Aidi injection, gingko Damo injection, lobaplatin for injection, compound cantharis capsule, Liqihuoxue dropping pill, qianliehuangaotong granules and many other superior varieties. Among these products, Aidi injection and cantharis capsule are two-phase anti-tumor drugs, among which the research of Aidi injection has reached the level of gene; the fourth generation of Ginkgo preparation, ginkgo Damo injection, is an effective treatment drug for heart, brain and peripheral circulation disorders, which has brought a lot of cardiovascular and cerebrovascular disease patients Lobaplatin for injection is a new drug in China. It is the third generation of platinum antitumor drugs. Compared with other platinum drugs, it has lower toxicity and less drug resistance. Liqihuoxue dropping pill is the original vaccine drug, which is the first-line drug for the treatment of cardiovascular diseases, and has great market potential. The company has established a good marketing network in the major cities of the country, equipped with a well-trained sales team, and realized the quality tracking service of the whole process from product to patient service. In order to promote the optimization of the pharmaceutical industry structure and improve the product concentration, in line with the development concept of accelerating M & A and independent innovation, the company has successively acquired such production-oriented pharmaceutical enterprises as Guilin Lijiang pharmaceutical, Yunnan Nanzhao pharmaceutical, Guizhou national pharmaceutical and Hainan Chang'an pharmaceutical in the past few years. The varieties of these enterprises have good market sales and have a very broad market prospect. In 2012, Yibai once again accelerated its pace of integration and acquisition, acquired 80% of the shares of Beijing ed Pharmaceutical Co., Ltd., and integrated the development, production and sales of genetically engineered drugs into Yibai's pharmaceutical and health industry chain.

本文链接： https://brand.waitui.com/74c56588c.html 联系电话：0851-84705590